Table 1.
Patient characteristics
| Characteristic | All (n = 63) % (no.) or median (range) |
HCC (n = 30) % (no.) or median (range) |
ICC (n = 25) % (no.) or median (range) |
|---|---|---|---|
| Age (years) | 69 (29–89) | 70.5 (34–89) | 68 (29–87) |
| Sex | |||
| Male | 52% (33) | 73% (22) | 20% (5) |
| Female | 48% (30) | 27% (8) | 80% (20) |
| Race/ethnicity | |||
| White | 75% (47) | 73% (22) | 76% (19) |
| Black | 5% (3) | 0% (0) | 8% (2) |
| Asian | 8% (5) | 13% (4) | 0% (0) |
| Hispanic | 6% (4) | 7% (2) | 8% (2) |
| Unknown | 6% (4) | 7% (2) | 8% (2) |
| ECOG | |||
| 0 | 41% (26) | 43% (13) | 28% (7) |
| 1 | 43% (27) | 33% (10) | 64% (16) |
| 2 | 8% (5) | 17% (5) | 0% (0) |
| 3 | 2% (1) | 3% (1) | 0% (0) |
| Tumor dimension, cm | 4.4 (0.6–17.0) | 4.3 (1.2–9.4) | 5.5 (0.6–17) |
| Previous therapy | |||
| Surgery | 13% (8) | 13% (4) | 12% (3) |
| TACE/TARE | 30% (19) | 53% (16) | 8% (2) |
| RFA | 6% (4) | 13% (4) | 0% (0) |
| Chemotherapy | 30% (19) | 10% (3) | 60% (15) |
| Radiation therapy | 10% (6) | 10% (3) | 12% (3) |
| None | 40% (25) | 37% (11) | 32% (8) |
HCC hepatocellular carcinoma, ICC intrahepatic cholangiocarcinoma, TACE transcatheter arterial chemoembolization, TARE transarterial radioembolization, RFA radiofrequency ablation